The 2-oxoglutarate/malate carrier extends the family of mitochondrial carriers capable of fatty acid and 2,4-dinitrophenol-activated proton transport. 2024

Kristina Žuna, and Tatyana Tyschuk, and Taraneh Beikbaghban, and Felix Sternberg, and Jürgen Kreiter, and Elena E Pohl
Physiology and Biophysics, Department of Biological Sciences and Pathobiology, University of Veterinary Medicine, Vienna, Austria.

OBJECTIVE Metabolic reprogramming in cancer cells has been linked to mitochondrial dysfunction. The mitochondrial 2-oxoglutarate/malate carrier (OGC) has been suggested as a potential target for preventing cancer progression. Although OGC is involved in the malate/aspartate shuttle, its exact role in cancer metabolism remains unclear. We aimed to investigate whether OGC may contribute to the alteration of mitochondrial inner membrane potential by transporting protons. METHODS The expression of OGC in mouse tissues and cancer cells was investigated by PCR and Western blot analysis. The proton transport function of recombinant murine OGC was evaluated by measuring the membrane conductance (Gm) of planar lipid bilayers. OGC-mediated substrate transport was measured in proteoliposomes using 14C-malate. RESULTS OGC increases proton Gm only in the presence of natural (long-chain fatty acids, FA) or chemical (2,4-dinitrophenol) protonophores. The increase in OGC activity directly correlates with the increase in the number of unsaturated bonds of the FA. OGC substrates and inhibitors compete with FA for the same protein binding site. Arginine 90 was identified as a critical amino acid for the binding of FA, ATP, 2-oxoglutarate, and malate, which is a first step towards understanding the OGC-mediated proton transport mechanism. CONCLUSIONS OGC extends the family of mitochondrial transporters with dual function: (i) metabolite transport and (ii) proton transport facilitated in the presence of protonophores. Elucidating the contribution of OGC to uncoupling may be essential for the design of targeted drugs for the treatment of cancer and other metabolic diseases.

UI MeSH Term Description Entries

Related Publications

Kristina Žuna, and Tatyana Tyschuk, and Taraneh Beikbaghban, and Felix Sternberg, and Jürgen Kreiter, and Elena E Pohl
December 1990, Biochemistry,
Kristina Žuna, and Tatyana Tyschuk, and Taraneh Beikbaghban, and Felix Sternberg, and Jürgen Kreiter, and Elena E Pohl
December 2000, American journal of physiology. Cell physiology,
Kristina Žuna, and Tatyana Tyschuk, and Taraneh Beikbaghban, and Felix Sternberg, and Jürgen Kreiter, and Elena E Pohl
February 2015, FEBS letters,
Kristina Žuna, and Tatyana Tyschuk, and Taraneh Beikbaghban, and Felix Sternberg, and Jürgen Kreiter, and Elena E Pohl
April 2018, Cancer research,
Kristina Žuna, and Tatyana Tyschuk, and Taraneh Beikbaghban, and Felix Sternberg, and Jürgen Kreiter, and Elena E Pohl
March 1974, Biochimica et biophysica acta,
Kristina Žuna, and Tatyana Tyschuk, and Taraneh Beikbaghban, and Felix Sternberg, and Jürgen Kreiter, and Elena E Pohl
March 1955, Applied microbiology,
Kristina Žuna, and Tatyana Tyschuk, and Taraneh Beikbaghban, and Felix Sternberg, and Jürgen Kreiter, and Elena E Pohl
February 1964, The Biochemical journal,
Kristina Žuna, and Tatyana Tyschuk, and Taraneh Beikbaghban, and Felix Sternberg, and Jürgen Kreiter, and Elena E Pohl
January 1992, DNA sequence : the journal of DNA sequencing and mapping,
Kristina Žuna, and Tatyana Tyschuk, and Taraneh Beikbaghban, and Felix Sternberg, and Jürgen Kreiter, and Elena E Pohl
May 1998, The Journal of pharmacology and experimental therapeutics,
Kristina Žuna, and Tatyana Tyschuk, and Taraneh Beikbaghban, and Felix Sternberg, and Jürgen Kreiter, and Elena E Pohl
August 1988, FEBS letters,
Copied contents to your clipboard!